Drugs / Remaxol
Remaxol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03418935 | Apr 2017 → Mar 2020 | obstructive jaundice | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
| Phase 3 | NCT03416062 | Apr 2017 → Feb 2020 | biliary tract cancer | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06183242 Comparator | May 2023 → Sep 2024 | intrahepatic cholestasis | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REMAXOL | “The drug REMAXOL® is a solution for infusion, which has shown high effectiveness in the syndrome of intrahepatic cholestasis in cases of liver dysfunction due to acute or...” NCT06183242 ↗ |
| Known as | Remaxol (succinate + methionine + inosine + nicotinamide) | “Remaxol (succinate + methionine + inosine + nicotinamide)” NCT03416062 ↗ |
| Route | Intravenous | “Solution for intravenous infusions” NCT03416062 ↗ |